查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726251

全球抗衰老药物市场：市场规模、份额、趋势分析（按产品、分销管道、应用和地区）、细分市场预测（2025-2030 年）

Senolytics And Anti-Aging Pharmaceuticals Market Size, Share & Trends Analysis Report By Product (Anti-Aging Pharmaceuticals), By Distribution Channel, By Application (Clinical Use / Off-label Therapeutics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

抗衰老药物市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球抗衰老药物市场规模预计到 2030 年将达到 63.9 亿美元，预测期内的复合年增长率为 7.59%。

主要驱动因素包括人口老化和预期寿命增加，以及老年族群中非传染性疾病盛行率上升，如阿兹海默症、帕金森氏症、癌症、糖尿病和骨质疏鬆症。人们对抗老化药物的认识不断提高以及这些抗衰老药物的采用率不断提高正在推动服务市场的成长。强大的研发投资进一步支持了市场。许多製药公司和学术机构正在投资开发抗衰老疗法、推进临床试验以及扩展有关如何有效针对衰老细胞的知识。随着基因治疗、干细胞治疗和免疫调节药物的积极研究，市场管道仍然强劲。

2025年2月，突破性发现FOXO4-DRI胜肽，这是一个针对老化细胞的新标靶。这种合成胜肽可抑制 FOXO4 与 p53 蛋白的相互作用并诱导衰老细胞凋亡。动物模型研究表明，它可以缓解与老龄化相关的症状，如肾衰竭和虚弱。这一新靶点已在体外和体内进行了研究。这些发现表明 FOXO4-DRI 具有针对衰老细胞和缓解与老龄化相关的病理的治疗潜力。

此外，2025 年 2 月，另一种新型老化细胞靶向分子，即蛋白水解靶向嵌合体(PROTAC) 被开发出来。 PROTAC 是双功能分子，透过结合 E3 连接酶、泛素化特定蛋白质并靶向它们进行蛋白酶体降解来诱导蛋白质降解。在细胞老化的背景下，已经开发出特定的 PROTAC，透过 BCL-xL/BCL-2 降解和 BRD4 降解等机制选择性地消除老化细胞。这些发现凸显了 PROTAC 选择性靶向和消除衰老细胞的治疗潜力，为治疗与老龄化相关的疾病和改善健康寿命提供了一种有希望的策略。

此外，人们正在深入研究细胞外囊泡 (EV) 和基于 miRNA 的衰老技术，以将药物引入临床试验。 EVs 可以调节基因表现并减少老化标记。这些囊泡已显示出在临床前模型中减少老化细胞负担和改善健康结果的潜力。针对这些 miRNA 的技术创新目前正在取得进展。

作为技术进步的一部分，人工智慧 (AI) 正在彻底改变新型抗衰老化合物的识别。正在开发两种人工智慧主导的方法，涉及深度神经网路筛检和简化药物开发。

这些策略倡议凸显了公司对抗老化药物创新、市场扩张和监管进步的关注，旨在改善全球患者的治疗效果。

抗老药物市场：分析概述

  • 根据产品类型，抗衰老药物领域在 2024 年占据市场主导地位，占总收入的 62.95%。这种增长归功于其广泛的治疗应用及其在医疗保健领域的既定地位，重点是预防和长寿。这些药物包括抗氧化剂、荷尔蒙调节剂和代谢调节剂，被广泛用于延缓老化、控制慢性疾病和改善日益注重健康的老年族群的生活品质。抗衰老领域，尤其是Dasatinib+槲皮素等组合，预计将因肿瘤学、免疫学和骨质疏鬆症方面的需求不断增加而获得关注。
  • 根据应用，临床试验/仿单标示外治疗领域在 2024 年占据市场最大收入份额，占整个市场的 59.24%。这种领导力是由Metformin、雷帕霉素和 NAD+ 增强剂等药物的临床再利用日益增多所推动的，这些药物旨在治疗与老龄化相关的疾病并延长健康寿命。随着越来越多的医疗保健提供者根据新证据采用这些治疗方法，他们在老年人慢性病管理中的治疗方法不断扩大。然而，由于消费者对主动健康和长寿解决方案的兴趣日益浓厚，消费者健康/长寿应用领域预计将在预测期内以最快的速度增长。
  • 根据分销管道，处方笺药部分在 2024 年成为主导通路，占总销售额的最大份额。这反映出，在强有力的法律规范和医生信任的支持下，Metformin和雷帕霉素等药物在临床上用于治疗与老龄化相关的疾病的应用日益增多。随着持续的临床检验和与标准治疗方案的整合，处方笺疗法预计将继续成为抗衰老龄化药物市场的核心。其他领域包括非处方药 (OTC)/补充剂、临床试验/同情使用等也促进了抗衰老药物市场的扩张。
  • 在 senolytics 抗衰老药物市场运营的主要企业包括诺华公司、罗氏控股公司、默克公司、辉瑞公司、赛诺菲公司、阿斯利康公司、强生公司、雅培实验室、太阳製药工业有限公司、Senolytic Therapeutics 公司和 AgeX Therapeutics。这些主要企业正在积极投资研发，推动创新并引领临床试验的进步，以应对全球人口老化所带来的复杂健康挑战。

目录

第一章 分析方法与范围

第二章执行摘要

3. 抗衰老药物市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 抗老药物市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
    • 定价分析
    • 管道分析

第四章 抗衰老药物市场：按类型分類的估计和趋势分析

  • 全球抗衰老药物市场：产品特定仪表板
  • 全球抗衰老药物市场：产品特定波动分析
  • 全球抗衰老药物市场：市场规模预测与趋势分析（以收益为准、按产品）
  • 抗老药物
  • 老化抑制剂

第五章 抗老药物市场：按分销管道的估计和趋势分析

  • 全球抗衰老药物市场：按分销管道分類的仪表板
  • 全球抗老药物市场：分销通路变化分析
  • 全球抗衰老药物市场：市场规模预测和趋势分析（按以收益为准和分销管道）
  • 全球抗衰老药物和抗衰老药品市场：分销通路仪表板
  • 全球抗老药物及抗老药物市场：流通通路变化分析
  • 全球抗衰老和抗衰老药物市场按分销管道和销售额划分
  • 处方药
  • 非处方药/补充剂
  • 临床试验/同情用药

第六章 抗衰老药物市场：按应用的估计和趋势分析

  • 全球抗衰老药物市场：按应用分類的仪表板
  • 全球抗老药物市场：应用趋势分析
  • 全球抗衰老药物市场：市场规模预测和趋势分析（以收益为准和应用）
  • 消费者健康/长寿
  • 临床使用/仿单标示外疗法

第七章 抗衰老药物市场：区域估计和趋势分析（按产品、应用和分销管道）

  • 区域仪表板
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Unity Biotechnology.
    • Novartis AG.
    • F. Hoffmann-La Roche AG.
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Sanofi
    • AstraZeneca
    • Johnson &Johnson Services Inc.
    • Abbott
    • Sun Pharmaceutical Industries Ltd
    • Senolytic Therapeutics Inc.
    • AgeX Therapeutics
Product Code: GVR-4-68040-555-0

Senolytics And Anti-Aging Pharmaceuticals Market Growth & Trends:

The global senolytics and anti-aging pharmaceuticals market size is anticipated to reach USD 6.39 billion by 2030 and is anticipated to expand at a CAGR of 7.59% during the forecast period, according to a new report by Grand View Research, Inc.

Key drivers include increasing aging population and life expectancy, rising prevalence of non-communicable diseases such as Alzheimer's, Parkinson's, cancer, diabetes and osteoporosis seen in geriatric population. Growing awareness of anti-aging drugs and rising adoption of these senolytic pharmaceuticals boosts the services market growth. The market is further supported by strong research and development investments. Numerous pharmaceutical companies and academic institutions are investing in the development of senolytic therapies, advancing clinical trials, and expanding knowledge of how to effectively target senescent cells The market pipeline remains robust, with active research in gene therapies, stem cell therapeutics, and immunomodulators.

In February 2025, FOXO4-DRI Peptide a novel target for targeting senescence cells was found innovated. This synthetic peptide disrupts the interaction between FOXO4 and p53 proteins, leading to apoptosis of senescent cells. Studies in animal models have demonstrated its potential to alleviate age-related conditions such as renal failure and frailty. In vitro and in vivo studies were conducted for this novel target. These findings suggest that FOXO4-DRI holds therapeutic potential for targeting senescent cells and mitigating age-related pathologies.

In addition, another novel senescent cell targeting molecules were developed in February 2025 known as Proteolysis-targeting chimeras (PROTACs). These are bifunctional molecules that induce the degradation of specific proteins by recruiting them to E3 ligases, leading to ubiquitination and subsequent proteasomal degradation. In the context of cellular senescence, certain PROTACs have been developed to selectively eliminate senescent cells through mechanisms such as BCL-xL/BCL-2 degradation and BRD4 degradation. These highlight the therapeutic potential of PROTACs in selectively targeting and eliminating senescent cells, offering a promising strategy for treating age-related diseases and improving healthspan.

Furthermore, a thorough research on extracellular vesicles (EVs) and miRNA-Based Senolytics technology is ongoing for bringing drugs to clinical trials. EVs can modulate gene expression to reduce senescence markers. These vesicles have demonstrated potential in reducing senescent cell burden and improving health outcomes in preclinical models. Advances are ongoing for innovations in targeting these miRNAs.

As part of technological advancements, artificial intelligence (AI) is revolutionizing the identification of novel anti-aging compounds. Two AI-driven approaches are being developed that includes Deep neural network screening and enhanced drug development efficiencies.

These strategic initiatives underscore the growing emphasis on Senolytics and anti-aging pharmaceuticals innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Senolytics And Anti-Aging Pharmaceuticals Market Report Highlights:

  • Based on product type, the Anti-aging Pharmaceuticals segment dominated the market in 2024, accounting for 62.95% of the total revenue. This strong performance is attributed to their broad therapeutic applications and well-established presence in preventive and longevity-focused healthcare. These pharmaceuticals-including antioxidants, hormone regulators, and metabolic modulators-are widely used to delay aging, manage chronic diseases, and improve quality of life among a growing, health-conscious elderly population. The Senolytic Agents segment, particularly combinations such as Dasatinib + Quercetin, is expected to gain traction due to increasing demand in oncology, immunology, and osteoporosis.
  • Based on application, the Clinical Use / Off-label Therapeutics segment led the market with the largest revenue share in 2024, accounting for 59.24% of the total market. This leadership is driven by the growing clinical repurposing of drugs such as Metformin, Rapamycin, and NAD+ boosters to target age-related diseases and extend healthspan. As more healthcare providers adopt these therapies based on emerging scientific evidence, their role in managing chronic conditions in older adults continues to expand. However, the Consumer Wellness / Longevity Use segment is expected to grow at the fastest rate over the forecast period, supported by increasing consumer interest in proactive health and longevity solutions.
  • Based on distribution channel, the Prescription-Based segment emerged as the dominant channel in 2024, accounting for the largest share of total revenue. This reflects the growing clinical use of drugs such as Metformin and Rapamycin for aging-related conditions, backed by robust regulatory frameworks and physician trust. With continued clinical validation and integration into standard care protocols, prescription-based therapies are expected to remain central to the anti-aging pharmaceuticals market. Other segments include Over-the-Counter (OTC)/Supplements and Clinical Trials/Compassionate Use, which also contribute to the expanding reach of anti-aging therapeutics.
  • Key players operating in the Senolytics and Anti-aging Pharmaceuticals market include Novartis AG, Roche Holding AG, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., AstraZeneca plc, Johnson & Johnson, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Senolytic Therapeutics Inc., and AgeX Therapeutics. These companies are actively investing in R&D, driving innovation, and leading advancements in clinical trials to address the complex health challenges of an aging global population.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Distribution Channel outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Senolytics & Anti-Aging Pharmaceuticals Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising anti-aging burden
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness about anti-aging treatment
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Senolytics & Anti-Aging Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Senolytics & Anti-Aging Pharmaceuticals Market: Product Estimates & Trend Analysis

  • 4.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Product Dashboard
  • 4.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Product Movement Analysis
  • 4.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Product, Revenue
  • 4.4. Anti-Aging Pharmaceuticals
    • 4.4.1. Anti-Aging Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Senolytic Agents
    • 4.5.1. Senolytic Agents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Dashboard
  • 5.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Movement Analysis
  • 5.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Distribution Channel, Revenue
  • 5.4. Prescription-Based
    • 5.4.1. Prescription-Based monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Over-the-Counter (OTC) / Supplements
    • 5.5.1. Over-the-Counter (OTC) / Supplements market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Clinical Trials / Compassionate Use
    • 5.6.1. Clinical Trials / Compassionate Use market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Senolytics & Anti-Aging Pharmaceuticals Market: Application Estimates & Trend Analysis

  • 6.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Application Dashboard
  • 6.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Application Movement Analysis
  • 6.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Application, Revenue
  • 6.4. Consumer Wellness / Longevity Use
    • 6.4.1. Consumer Wellness / Longevity Use market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Clinical Use / Off-label Therapeutics
    • 6.5.1. Clinical Use / Off-label Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Senolytics & Anti-Aging Pharmaceuticals Market: Regional Estimates & Trend Analysis by Product, Application, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Unity Biotechnology.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Novartis AG.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche AG.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Pfizer Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sanofi
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Johnson & Johnson Services Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Abbott
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Sun Pharmaceutical Industries Ltd
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Senolytic Therapeutics Inc.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. AgeX Therapeutics
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 3 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Route of, 2018 - 2030 (USD Million)
  • Table 4 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 8 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 17 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 France Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 24 France Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 30 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 China Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 36 China Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 China Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 38 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 India Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 India Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 44 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Senolytics & Anti-Aging Pharmaceuticals market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and Distribution Channel segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Senolytics & Anti-Aging Pharmaceuticals market: Product outlook and key takeaways
  • Fig. 17 Senolytics & Anti-Aging Pharmaceuticals market: Product movement analysis
  • Fig. 18 Anti-Aging Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Senolytic Agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Senolytics & Anti-Aging Pharmaceuticals market: Distribution Channel outlook and key takeaways
  • Fig. 21 Senolytics & Anti-Aging Pharmaceuticals market: Distribution Channel movement analysis
  • Fig. 22 Prescription-Based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Over-the-Counter (OTC) / Supplements market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Clinical Trials / Compassionate Use market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Senolytics & Anti-Aging Pharmaceuticals market: Application outlook and key takeaways
  • Fig. 26 Senolytics & Anti-Aging Pharmaceuticals market: Application channel movement analysis
  • Fig. 27 Consumer Wellness / Longevity Use market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Clinical Use / Off-label Therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Senolytics & Anti-Aging Pharmaceuticals market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Key country dynamics
  • Fig. 34 Target disease prevalence
  • Fig. 35 U.S. senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Target disease prevalence
  • Fig. 38 Canada senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Target disease prevalence
  • Fig. 42 Europe senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Target disease prevalence
  • Fig. 45 UK senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Target disease prevalence
  • Fig. 48 Germany senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Target disease prevalence
  • Fig. 51 France senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Target disease prevalence
  • Fig. 54 Spain senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 Italy senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 Denmark senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 Sweden senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Norway senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of Europe senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 Japan senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Target disease prevalence
  • Fig. 74 China senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Target disease prevalence
  • Fig. 77 India senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Target disease prevalence
  • Fig. 80 Australia senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Thailand senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 South Korea senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Rest of Asia Pacific senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Latin America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 Brazil senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Argentina senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Rest of Latin America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 MEA senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 South Africa senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Target disease prevalence
  • Fig. 100 Saudi Arabia senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Target disease prevalence
  • Fig. 103 UAE senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Target disease prevalence
  • Fig. 106 Kuwait senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Rest of MEA senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)